I suspect a DNA vaccine will have lower cost of manufacture than the known competitors -- quality control should also be less an issue. However, Admedus does need to at least match clinical outcomes of competitors.
Depending on any adjuncts required & delivery method, I would hope any products coming out of Admedus are stable at room temperature - not sure about the competitors. Also interesting is whether this vaccine will be a candidate for nano-patch delivery rather than traditional injection. That tech was developed in Qld too -- but now owned by a US company commercialising it.
Phase 2 commencing this year is good news.
- Forums
- ASX - By Stock
- AVR
- Ann: Admedus announces further data from HSV-2 Trial
Ann: Admedus announces further data from HSV-2 Trial, page-76
-
- There are more pages in this discussion • 93 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add AVR (ASX) to my watchlist
|
|||||
Last
$18.00 |
Change
0.000(0.00%) |
Mkt cap ! $346.0M |
Open | High | Low | Value | Volume |
$18.00 | $18.10 | $17.70 | $58.64K | 3.27K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 109 | $18.00 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$18.10 | 700 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 48 | 17.750 |
1 | 26 | 17.650 |
1 | 200 | 17.560 |
1 | 500 | 17.550 |
1 | 1 | 17.510 |
Price($) | Vol. | No. |
---|---|---|
18.100 | 700 | 1 |
18.300 | 150 | 1 |
18.500 | 43 | 1 |
18.690 | 550 | 1 |
18.750 | 143 | 1 |
Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |